Author details

Full Name

Janet Schnee

Affiliation

ORCID

Career Start Year

1987

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36881400	Comparison of Investigator-Reported and Centrally Adjudicated HeartÂ FailureÂ Outcomes in the EMPEROR-Reduced Trial.	JACC Heart Fail	2023
34878502	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction.	Eur Heart J	2022
36471037	Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved.	Nat Med	2022
34556318	Prognostic Importance of NT-proBNP andÂ Effect of Empagliflozin in the EMPEROR-Reduced Trial.	J Am Coll Cardiol	2021
33459776	Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.	Eur Heart J	2021
34184057	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.	Eur Heart J	2021
33095032	Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.	Circulation	2021
34449189	Empagliflozin in Heart Failure with a Preserved Ejection Fraction.	N Engl J Med	2021
33251670	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.	Eur J Heart Fail	2020
31523904	Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.	European Journal of Heart Failure	2019
31584231	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.	Eur J Heart Fail	2019
26446456	A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.	Thrombosis and Haemostasis	2015
24392958	Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US.	Current Medical Research and Opinion	2014
27201505	Dabigatran Users With Non-Valvular Atrial Fibrillation in the Us: A Characterization of Dabigatran Initiators and Switchers.	Value in Health	2014
22704461	Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: findings from four Phase 3 trials.	Thrombosis Research	2012
21225098	Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.	Thrombosis and Haemostasis	2011
20434759	Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.	Thrombosis Research	2010
18534438	Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.	Journal of Arthroplasty	2009
19966341	Dabigatran versus warfarin in the treatment of acute venous thromboembolism.	New England Journal of Medicine	2009
17869635	Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.	Lancet, The	2007
17764540	Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.	Journal of Thrombosis and Haemostasis	2007
15120833	Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart.	J Am Coll Cardiol	2004
11181563	Human homologs of the Xenopus oocyte cortical granule lectin XL35.	Glycobiology	2001
10773230	Angiotensin II, adhesion, and cardiac fibrosis.	Cardiovascular Research	2000
10642310	Angiotensin II enhances integrin and alpha-actinin expression in adult rat cardiac fibroblasts.	Hypertension	2000
8446952	High-level expression of antibody-plasminogen activator fusion proteins in hybridoma cells.	Thrombosis Research	1993
3116546	Construction and expression of a recombinant antibody-targeted plasminogen activator.	Proc Natl Acad Sci U S A	1987